- Home
- RFI vs SEPN Comparison
RFI vs SEPN Comparison
Compare RFI & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFI
- SEPN
- Stock Information
- Founded
- RFI 1992
- SEPN 2022
- Country
- RFI United States
- SEPN United States
- Employees
- RFI N/A
- SEPN N/A
- Industry
- RFI Investment Managers
- SEPN
- Sector
- RFI Finance
- SEPN
- Exchange
- RFI Nasdaq
- SEPN NYSE
- Market Cap
- RFI 312.2M
- SEPN 311.6M
- IPO Year
- RFI N/A
- SEPN 2024
- Fundamental
- Price
- RFI $12.04
- SEPN $6.73
- Analyst Decision
- RFI
- SEPN Buy
- Analyst Count
- RFI 0
- SEPN 4
- Target Price
- RFI N/A
- SEPN $33.00
- AVG Volume (30 Days)
- RFI 69.8K
- SEPN 193.7K
- Earning Date
- RFI 01-01-0001
- SEPN 05-23-2025
- Dividend Yield
- RFI 8.25%
- SEPN N/A
- EPS Growth
- RFI N/A
- SEPN N/A
- EPS
- RFI N/A
- SEPN N/A
- Revenue
- RFI N/A
- SEPN $1,075,000.00
- Revenue This Year
- RFI N/A
- SEPN N/A
- Revenue Next Year
- RFI N/A
- SEPN N/A
- P/E Ratio
- RFI N/A
- SEPN N/A
- Revenue Growth
- RFI N/A
- SEPN 611.92
- 52 Week Low
- RFI $9.62
- SEPN $4.17
- 52 Week High
- RFI $12.52
- SEPN $28.99
- Technical
- Relative Strength Index (RSI)
- RFI 55.42
- SEPN N/A
- Support Level
- RFI $11.94
- SEPN N/A
- Resistance Level
- RFI $12.24
- SEPN N/A
- Average True Range (ATR)
- RFI 0.16
- SEPN 0.00
- MACD
- RFI 0.04
- SEPN 0.00
- Stochastic Oscillator
- RFI 70.59
- SEPN 0.00
About RFI Cohen & Steers Total Return Realty Fund Inc.
Cohen & Steers Total Return Realty Fund Inc is a diversified, closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.